O'NEIL PATRICK R.

IONS EVP/CLO O'Neil sells 10,148 shares at $75.25; stock down 11.8% in 30d; unprofitable company.

O'NEIL PATRICK R., EVP CLO & General Counsel, sold 10,148 shares of IONIS PHARMACEUTICALS INC at $75.25 on 2026-03-09, reducing his holdings by 14.0% to 62,211 shares. The stock has declined 11.8% over the 30 days following the transaction and is currently at $74.79, down 13.5% from its 52-week high of $86.50. At IONIS specifically, his prior 3 measurable sales all generated positive 90-day returns (+15.0%, +14.0%, +16.9%), meaning the stock rose after each of those sales—none were well-timed as sell decisions. IONIS remains unprofitable with net income of $-128,606,000.00 in its most recent fiscal year, despite strong quarterly revenue of $156,719,000.00 and annual revenue growth of +33.8%, creating a tension between growth momentum and profitability that warrants investor attention.

EVP CLO O'NEIL sells 6.2K IONS shares at $83.53; stock near 52-week high ($83.88), trading +4.3% 30d. Company unprofitable, revenue down 10.5% YoY.

O'NEIL PATRICK R. sold 6,179 shares at $83.53, reducing holdings by 7.9% during a period when IONS is trading near its 52-week high of $83.88. This is his second sale in 14 days (prior sale on 2026-01-16), suggesting a deliberate paring of exposure. His same-ticker history shows 4 prior measurable sales with 0 of 4 well-timed at the 90-day mark—the stock rose after each sale. Against this pattern, the timing characterization is neutral: neither the cross-ticker track record (8.33% well-timed rate on 13 prior sells) nor the IONS-specific data provides strong directional conviction. The broader context is concerning: the company is unprofitable with net income of $-128.6M in the latest quarter and annual revenue down 10.5%, yet the stock is trading at a $13.5B market cap and near all-time highs. The consecutive sales 14 days apart merit observation for any forward messaging about operational momentum.

EVP & CLO O'Neill sells 9,191 shares of IONS at $75.84; stock up 8.4% in 90d but insider's 5 prior IONS sales all saw positive 90-day returns

Patrick O'Neill, EVP CLO & General Counsel, sold 9,191 shares at $75.84 on 2026-01-16, reducing his holdings by 12.2% to 66,171 shares. The stock has appreciated 8.4% over the past 90 days and currently trades at $77.53, roughly 6.8% below its 52-week high of $83.17. Notably, across O'Neill's five prior sales of IONS stock (all occurring in September and October 2025), the stock delivered positive 90-day returns in every instance, ranging from +14.0% to +23.7%, with none of these prior sales materially preceding a decline. The company faces material headwinds: revenue declined 10.5% year-over-year (latest quarter $156.7M), the company posted a net loss of $128.6M in the most recent period, and its full-year results were unprofitable. While O'Neill's cross-ticker track record shows an 8.33% well-timed sell rate across 12 prior open-market sales, his demonstrated pattern at IONS has been consistently followed by share price appreciation rather than decline.

EVP CLO Patrick O'Neil sells 13,441 shares at blended $69.74 as IONS stock hits 52-week high of $69.96

Patrick O'Neil, EVP Chief Legal Officer, executed 2 separate sales totaling 13,441 shares for $937,337.63 at a blended average price of $69.74 on 2025-10-06, reducing his holdings by 20.0% from 67,330 to 53,889 shares. The transactions occurred precisely as Ionis stock reached its 52-week high of $69.96, with the stock up 14.7% over 30 days and 65.1% over 90 days. However, his same-ticker transaction history at IONS shows 5 prior sells with no yet-measurable outcomes, limiting any inference about his predictive accuracy at this specific company. The company's fundamentals show fiscal year revenue declined 10.5% year-over-year and was unprofitable on a full-year basis, though the latest quarter reported $123.6M in net income on $452.0M revenue. The timing at the 52-week high following a significant rally warrants close observation of near-term price action and whether additional insider activity signals broader capital allocation intentions.

CLO O'Neill sells 64.7K IONS shares for $4.4M at $67.69, reducing stake by 53.1% in 2 transactions

Patrick R. O'Neill, EVP, CLO & General Counsel, executed 2 separate sales totaling 64,664 shares for $4,377,054.43 at a blended average price of $67.69 on 2025-10-02, reducing his holdings from 121,794 shares to 57,130 shares (a 53.1% reduction). This marks a significant liquidation of his position at the stock's current 52-week high of $68.40, following a 30-day rally of +19.0% and a 90-day surge of +59.1%. O'Neill has established a pattern of near-daily selling at IONS over five prior transactions in September 2025, though outcomes on those trades remain unmeasurable. His cross-ticker track record of 8 prior sales shows an average 90-day return of -14.7% with a well-timed rate of 100.0%, indicating his historical sells have occurred before subsequent stock declines. The company's fundamentals show annual revenue declined 10.5% year-over-year and reported negative full-year net income, despite the current quarter showing $123.6M in net income on $452.0M revenue.

EVP & CLO Patrick O'Neil sold 25,300 shares at blended $64.62 for $1.6M on 2025-09-29/30

Patrick O'Neil, EVP, CLO & General Counsel, executed two separate sales totaling 25,300 shares for $1,634,921.48 (blended average $64.62) on 2025-09-29 and 2025-09-30, reducing his holdings by 30.7% to 57.1K shares. This transaction occurred as the stock sits at its 52-week high of $65.80, with a 30-day price surge of 54.3% and 90-day gain of 53.0%, creating a backdrop of strong recent momentum. Notably, O'Neil has executed 5 consecutive sells at IONS within the span of 2025-09-02 through 2025-09-30, and while his cross-ticker track record shows a 100% well-timed rate on 6 prior sells, outcomes from those same-ticker transactions at IONS are not yet measurable. The combination of sustained selling activity by a senior executive during a period of accelerated stock appreciation warrants investor attention to understand the underlying motivation and any near-term company developments.

EVP CLO O'Neil sells 21,000 IONS shares at $64.56 (–26.9% of holdings); stock up 79.9% in 90 days at multi-year high

O'NEIL PATRICK R. executed 2 separate sales totaling 21,000 shares for $1,355,661.30 on 2025-09-09, reducing his stake by 26.9% to 57,130 shares. The sales occurred at $64.56, near the 52-week high of $64.40 and just 0.6% below the peak. The stock has surged 79.9% over the prior 90 days and 54.6% over 30 days, placing the transaction near a significant price inflection. Contextually, the company reported a full-year net loss despite recent quarterly profitability ($123.6M net income in latest quarter) and declining annual revenue growth of –10.5%, signaling potential earnings volatility. The insider's cross-ticker track record shows a 100% well-timed rate on 4 prior sells (measuring a 90-day window); however, his prior 3 sales at IONS within the last week remain unmeasurable. This filing represents a material reduction in his position at a cyclical price peak amid mixed fundamental signals.

EVP CLO O'Neil sold 89,900 shares (61.1% of holdings) for $5.4M across 3 transactions at $54.51–$61.42

Patrick R. O'Neil, EVP, CLO & General Counsel, executed 3 separate open-market sales totaling 89,900 shares for $5,396,843.39, reducing his stake from 147,030 to 57,130 shares (61.1% reduction). The sales occurred at prices ranging from $54.51 to $61.42, with a blended average of $60.03 near the current price of $59.35. In his cross-ticker track record, O'Neil's 1 prior sell demonstrated a 90-day well-timed rate of 100.00%, and his prior IONS trade (December 2023 sell) showed a 90-day return of -14.7%, indicating the stock declined after that sale. This current transaction occurs as IONS trades at -1.9% from its 52-week high of $60.49 and is up 37.9% over 30 days and 68.2% over 90 days. Against this backdrop of recent gains, the magnitude of the position reduction—selling nearly two-thirds of holdings—merits investor attention alongside the company's recent headwinds: annual revenue declined 10.5% year-over-year, and the company was unprofitable over its most recent full fiscal year despite posting a $123.6M net income in the latest quarter.